Next Article in Journal
Expression of E-CADHERIN and miR-200b in Different Forms of Endometriosis
Previous Article in Journal
Long-Term Outcomes of Patients with Poor Prognostic Factors Following Transanal Endoscopic Microsurgery (TEMS) for Early Rectal Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Commentary

Should We Accept the Epiligament Theory About the Differences in the Healing Potential of the Medial Collateral and the Anterior Cruciate Ligament?

by
Georgi P. Georgiev
1,*,
Lyubomir Gaydarski
2 and
Boycho Landzhov
2
1
Department of Orthopedics and Traumatology, University Hospital Queen Giovanna-ISUL, Medical University of Sofia, 1527 Sofia, Bulgaria
2
Department of Anatomy, Histology and Embryology, Medical University of Sofia, 1431 Sofia, Bulgaria
*
Author to whom correspondence should be addressed.
Biomedicines 2025, 13(2), 522; https://doi.org/10.3390/biomedicines13020522
Submission received: 29 January 2025 / Revised: 14 February 2025 / Accepted: 17 February 2025 / Published: 19 February 2025
(This article belongs to the Section Molecular and Translational Medicine)

Abstract

:
The epiligament (EL), described in 1990 as a connective tissue layer distinguishable from the ligament proper, has only recently gained recognition for its critical role in ligament function and repair. Previously overlooked, the EL is now understood to be a dynamic structure, particularly in the context of medial collateral ligament (MCL) healing. Rat model studies demonstrate that the EL actively contributes to ligament repair by serving as a source of cells and blood vessels, findings later corroborated in human studies. The EL’s role in spontaneous MCL healing highlights its importance, raising the question of whether differences in EL morphology and activity contribute to the poor healing capacity of the anterior cruciate ligament (ACL). Comparative studies reveal significant disparities in EL cellularity and activity between the ACL and MCL. The EL of the MCL is hypercellular, with robust expression markers like α-smooth muscle actin (α-SMA) and collagen types III and V, essential for tissue remodeling and structural integrity. Conversely, the ACL’s EL is less vascularized and exhibits weaker expression of these markers. While vascular endothelial growth factor (VEGF) promotes angiogenesis, its effectiveness is limited in the ACL due to restricted vascularization. Similarly, CD34, a progenitor cell marker, is more prominently expressed in the MCL’s EL, further supporting its superior healing potential. These findings suggest that the EL’s distinct structural and functional attributes are key determinants of ligament healing. Targeting the EL’s regenerative properties offers a promising therapeutic strategy, particularly for improving ACL repair outcomes. Further research is necessary to validate and expand these findings.

1. Introduction

Ligamentous knee injuries are common in sports and can occur through a variety of mechanisms. If left untreated, these injuries may lead to persistent instability, progressive damage to the menisci and articular cartilage, and early-onset osteoarthritis [1,2]. The MCL is the most frequently injured knee ligament, especially in sports like soccer, skiing, and ice hockey. These injuries typically result from a direct valgus force to the knee or during cutting maneuvers when an athlete plants their foot and suddenly changes direction or speed [3,4,5,6,7,8,9]. MCL injuries have an incidence rate ranging from 0.24 to 7.3 per 1000 people, with a male-to-female ratio of 2:1 [10,11]. The MCL accounts for up to 40% of all knee ligament injuries [12] and 7.9% of all knee injuries in athletes [13].
The ACL is also one of the most commonly injured knee structures [14], with ACL injuries occurring at 68.6 cases per 100,000 people in the United States [15,16]. These injuries usually happen during sports activities involving twisting and cutting [14,17]. ACL injuries are a significant risk factor for developing osteoarthritis [18]. Over time, the incidence of ACL injuries has steadily increased, making them a significant concern in orthopedic practice. The ACL has a limited capacity for spontaneous healing, unlike the MCL [4,19]. Numerous studies using animal models have explored the healing potential of knee ligaments, offering various explanations for the differences in healing between the two [20,21,22]. Unlike the ACL, the MCL is an extra-articular ligament that can heal naturally, showing considerable recovery potential [23]. This healing capacity has been demonstrated in histological studies, clinical observations, and radiological assessments [20,23]. However, surgical alignment, immobilization, and early protected range of motion can influence healing [23]. Zhang et al. [24] found that stem cells derived from the ACL show inherent differences compared to those from the MCL, which could help explain the disparity in healing abilities between the two ligaments. Despite extensive research, several key questions remain unanswered [24].
This commentary draws attention to a different theory regarding the MCL’s healing and the ACL’s failure. Why revisit these ligaments? Are their biology and morphology not already well understood? While much has been learned about the differing healing capacities of the ACL and MCL, and various theories attempt to explain these differences, the existing knowledge remains incomplete [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,21,22,23,24]. A recent proposal highlights the potential role of the epiligament (EL) in MCL healing, sparking interest [19,20,25,26,27,28,29,30]. However, is the EL a well-studied structure? Unlike previous studies that have examined ligament healing exclusively in either animal models or human subjects, the research group led by Georgiev conducted a comparative analysis of the EL in a rat model and humans. This approach enabled them to draw more robust conclusions regarding the role of the EL in ligament healing. Moreover, could this theory also shed light on the limited healing capacity of the ACL?

2. Main Text

Although the treatment of ligament injuries has significantly improved over the years, many questions remain regarding the completeness of ligament healing [31]. Various studies have shown that while the MCL typically heals spontaneously, it is not fully restored [19,25]. It is well established that the ligament healing process depends on several factors, including anatomical location, associated injuries, and different treatment modalities. These modalities include tissue engineering, nonsteroidal anti-inflammatory drugs, local corticosteroids, hyperbaric oxygen therapy, growth factors, ultrasound or electrical stimulation, laser therapy, and gene therapy [19,25,31,32,33].
The EL was first identified by Bray et al. [34] as a thin layer of connective tissue surrounding the ligament. Chowdhury et al. [35] examined the EL of the MCL in rabbits and concluded that the tissue comprises collagen fiber bundles, three distinct types of cells (spinous-shaped, cuboidal-shaped, and fat cells), and a neurovascular network that periodically extends into the MCL [35]. More recently, Georgiev et al. [20] described the MCL EL as a source of fibroblasts, progenitor cells, and blood vessels that migrate through the endoligament into the ligament body. These authors emphasize its critical role in ligament function and healing. Nonetheless, how was this role demonstrated?
Studies by Georgiev et al. [20,25] using MCL injury models have shown that fibroblasts within the EL are not static; instead, they actively synthesize various collagen types, matrix metalloproteinases, decorin, fibronectin, and fibromodulin. These molecules are widely recognized as key contributors to ligament degradation, proliferation, and remodeling following trauma [20,25].
Following investigations of the EL in rats, a study was conducted to examine this tissue in humans. To explore the proposed role of the EL and address the question of why the ACL fails to heal effectively, Georgiev et al. [26] analyzed the morphology of the mid-substance of the EL in the human MCL and ACL. They formulated a theory regarding ACL healing failure by detailing the EL’s morphology and comparing its characteristics between these two ligaments.
What is currently known about ACL healing failure? Georgiev et al. [26] reviewed the existing theories in the literature, highlighting key factors contributing to the ACL’s limited healing potential. Differences in the ultrastructural characteristics of connective tissue cells between the MCL and ACL have been observed [36]. Additionally, variations in fibroblast proliferation potential [22,37] and elevated nitric oxide levels in the ACL, which inhibit collagen and proteoglycan synthesis, have been identified [21]. The MCL demonstrates a superior capacity to enhance blood flow and angiogenesis following injury [38]. Furthermore, stem cells exhibit ligament-specific properties that differ between the MCL and ACL [24,39], and differential expression of matrix metalloproteinases (MMP-2, -9, and -13) also play a significant role [20,40].
The ACL’s poor healing is also attributed to the inability of cells and blood vessels to bridge the ruptured ends effectively and the inadequate wound filling in the intra-articular environment [41]. The intra-articular ACL is exposed to synovial fluid, inhibiting fibroblast activity [42]. Additionally, plasmin in the synovial fluid degrades the fibrin clot, further impeding healing [43].
What does the EL theory propose, and what evidence supports it compared to previous theories? Table 1 summarizes the current understanding of ACL healing failure and contrasts it with the EL-based theory, offering fresh insights into the differences in healing potential.
These findings evaluate current theories and lay the groundwork for a new perspective on the limited healing capacity of the ACL. Research indicates that cell density is significantly higher in the EL of the MCL compared to the ACL [26,30]. Additionally, the EL of the MCL exhibits a stronger expression of key collagens than that of the ACL. Based on these observations, along with the established roles and functional activity of the EL, a logical explanation for the differing healing potentials of these ligaments has been proposed [26]. The EL theory accounts for the lack of healing observed in middle-third ACL injuries. However, how was the EL theory validated?
Firstly, Georgiev et al. [19,20,25,26,27,30] investigated the structural and functional differences between the ELs of the mid substance of ACL and MCL in both human and animal models, with a focus on understanding the superior healing capacity of the MCL. Their findings highlight that the EL of the MCL contains a higher density of fibroblasts, greater collagen type III and V expression, and more robust vascularization compared to the ACL’s EL [19,20,26]. These features enable the MCL to form granulation tissue, promote angiogenesis, and synthesize collagen more effectively during the early stages of healing. In contrast, the EL of the ACL is less cellular and vascularized, which correlates with its limited healing potential [19,20,26]. Immunohistochemical analyses revealed stronger collagen expression and more pronounced healing-related activities in the MCL’s EL compared to the ACL [19,20,26]. These findings suggest that targeting the EL’s cellular and molecular components could enhance ligament repair strategies, particularly for the ACL, which inherently exhibits poor healing capabilities [19,20,26].
Further exploring the EL’s role, Georgiev et al. [27] demonstrated that the EL serves as a reservoir of fibroblasts, progenitor cells, and blood vessels crucial for ligament repair. Their immunohistochemical analyses in the ACL and MCL midsection revealed variable expression levels of vascular endothelial growth factor (VEGF), CD34, and α-smooth muscle actin (α-SMA). While the ACL exhibited slightly higher overall expression of these markers, its limited fibroblast density and reduced collagen expression in the EL hindered its healing capacity. VEGF and CD34, primarily localized in vascular zones, facilitated angiogenesis and vasculogenesis, while α-SMA is associated with myofibroblast activity, aiding structural restoration. These findings underscore the EL’s role in differential ligament healing and highlight the potential for targeted therapies to enhance EL-mediated repair [27].
In addition, Georgiev et al. [28] recently examined the healing differences between the proximal and distal parts of the ACL, further validating the EL theory. Their study found that the proximal EL exhibits higher α-SMA expression, indicating a more significant role in tissue remodeling. In contrast, the distal EL shows elevated CD34 levels, supporting vascularization and progenitor cell activity. Both regions demonstrated significantly higher cell densities compared to the mid-substance of the ACL, suggesting complementary roles in the healing process. These results emphasize the importance of preserving or enhancing EL activity during ACL repair strategies, potentially improving healing outcomes for injuries to this ligament and the better susceptibility to repair of proximal and distal ACL lesions [28].
Similarly, Georgiev et al. [29] investigated the differences in healing capacities between the human knee’s proximal and distal parts of the MCL. The distal EL exhibited higher cell density and greater expression of α-SMA, indicating superior healing potential compared to the proximal part. While CD34 expression was weak in both regions, VEGF was present in the blood vessels without significant regional differences. These findings support the EL theory, highlighting the distal EL’s prominent role in ligament recovery. Targeting the distal EL’s cellular and molecular properties could provide therapeutic benefits for enhancing MCL repair [29]. Table 2 provides a detailed comparison of the structural, cellular, and molecular differences between the EL of the ACL and MCL, focusing on their respective healing capacities. It highlights the distinct regional variations (proximal, mid-substance, and distal) in both ligaments, shedding light on the critical factors influencing healing potential. The table underscores the therapeutic implications of these findings, particularly the potential benefits of targeting the EL to enhance healing outcomes. This comparison offers valuable insights into why the MCL exhibits superior healing compared to the ACL to guide future strategies for ligament repair.
In the current literature, most studies focus on ligament healing in either animal models or human subjects. However, Georgiev and his research team not only investigated the role of the EL in ligament healing but have also advanced EL theory by conducting a comparative analysis across both animal models and translating their findings to humans. Their work provides deeper insights into EL function and its involvement in ligament repair, establishing a new foundation for future research.

3. Conclusions

Collectively, the studies discussed highlight the pivotal role of EL in ligament healing, emphasizing its essential contributions to cellular migration, angiogenesis, and collagen synthesis. The EL theory offers a comprehensive framework to understand the distinct healing potentials of the ACL and MCL and the variations within their proximal, midsection, and distal regions. By harnessing the regenerative properties of the EL, targeted therapeutic strategies have the potential to markedly enhance outcomes for ligament injuries, especially for the ACL, which inherently exhibits limited healing capacity.
Despite advancements in understanding the EL theory and its implications for ligament healing, its practical application by morphologists and knee surgeons remains uncertain. Whether this theory will gain widespread acceptance as a key explanation for ACL healing challenges is yet to be determined. Nevertheless, ongoing research should focus on unraveling the molecular and cellular mechanisms of the EL, paving the way for innovative and effective treatments in ligament repair.

Author Contributions

Conceptualization—G.P.G.; writing—review and editing—L.G.; supervision—B.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ELEpiligament
ACLAnterior cruciate ligament
MCLMedial collateral ligament
MMPMatrix Metalloproteinase
α-SMAα-Smooth Muscle Actin
VEGFVascular Endothelial Growth Factor

References

  1. Irarrázaval, S.; Yaseen, Z.; Guenther, D.; Fu, F.H. Clinical Management of Ligament Injuries of the Knee and Postoperative Rehabilitation. In Regenerative Strategies for the Treatment of Knee Joint Disabilities; Oliveira, J., Reis, R., Eds.; Studies in Mechanobiology, Tissue Engineering and Biomaterials; Springer: Cham, Switzerland, 2017; Volume 21, pp. 299–318. [Google Scholar]
  2. Baren, J.P.; Rowbotham, E.; Wuertzer, S.D.; Grainger, A.J. Knee: Ligament Reconstruction. In Postoperative Imaging of Sports Injuries; Rowbotham, E., Grainger, A.J., Eds.; Springer: Cham, Switzerland, 2020; pp. 93–106. [Google Scholar]
  3. Andrews, K.; Lu, A.; McKean, L.; Ebraheim, N. Review: Medial Collateral Ligament Injuries. J. Orthop. 2017, 14, 550–554. [Google Scholar] [CrossRef]
  4. Wijdicks, C.A.; Griffith, C.J.; Johansen, S.; Engebretsen, L.; LaPrade, R.F. Injuries to the Medial Collateral Ligament and Associated Medial Structures of the Knee. J. Bone Joint Surg. Am. 2010, 92, 1266–1280. [Google Scholar] [CrossRef] [PubMed]
  5. Tognolo, L.; Coraci, D.; Bernini, A.; Masiero, S. Treatment of Medial Collateral Ligament Injuries of the Knee with Focused Extracorporeal Shockwave Therapy: A Case Report. Appl. Sci. 2022, 12, 234. [Google Scholar] [CrossRef]
  6. Robinson, J.; Bull, A.; Thomas, R.; Amis, A. The Role of the Medial Collateral Ligament and Posteromedial Capsule in Controlling Knee Laxity. Am. J. Sports Med. 2006, 34, 1815–1823. [Google Scholar] [CrossRef]
  7. Phisitkul, P.; James, S.L.; Wolf, B.R.; Amendola, A. MCL Injuries of the Knee: Current Concepts Review. Iowa Orthop. J. 2006, 26, 77–90. [Google Scholar]
  8. Vosoughi, F.; Rezaei Dogahe, R.; Nuri, A.; Ayati Firoozabadi, M.; Mortazavi, J. Medial Collateral Ligament Injury of the Knee: A Review on Current Concept and Management. Arch. Bone Jt. Surg. 2021, 9, 255–262. [Google Scholar]
  9. Lee, C.-S.; Jeon, O.-H.; Han, S.-B.; Jang, K.-M. Mesenchymal Stem Cells for Enhanced Healing of the Medial Collateral Ligament of the Knee Joint. Medicina 2023, 59, 725. [Google Scholar] [CrossRef] [PubMed]
  10. DeLong, J.; Waterman, B. Surgical Techniques for the Reconstruction of Medial Collateral Ligament and Posteromedial Corner Injuries of the Knee: A Systematic Review. Arthroscopy 2015, 31, 2258–2272. [Google Scholar] [CrossRef]
  11. Memarzadeh, A.; Melton, J. Medial Collateral Ligament of the Knee: Anatomy, Management and Surgical Techniques for Reconstruction. Orthop. Trauma 2019, 33, 91–99. [Google Scholar] [CrossRef]
  12. Bollen, S. Epidemiology of Knee Injuries: Diagnosis and Triage. Br. J. Sports Med. 2000, 34, 227–228. [Google Scholar] [CrossRef] [PubMed]
  13. Majewski, M.; Susanne, H.; Klaus, S. Epidemiology of Athletic Knee Injuries: A 10-Year Study. Knee 2006, 13, 184–188. [Google Scholar] [CrossRef] [PubMed]
  14. Kiapour, A.M.; Murray, M.M. Basic Science of Anterior Cruciate Ligament Injury and Repair. Bone Jt. Res. 2014, 3, 20–31. [Google Scholar] [CrossRef] [PubMed]
  15. Mall, N.A.; Chalmers, P.N.; Moric, M.; Tanaka, M.J.; Cole, B.J.; Bach, B.R., Jr.; Paletta, G.A., Jr. Incidence and Trends of Anterior Cruciate Ligament Reconstruction in the United States. Am. J. Sports Med. 2014, 42, 2363–2370. [Google Scholar] [CrossRef] [PubMed]
  16. Sanders, T.L.; Maradit Kremers, H.; Bryan, A.J.; Larson, D.R.; Dahm, D.L.; Levy, B.A.; Stuart, M.J.; Krych, A.J. Incidence of Anterior Cruciate Ligament Tears and Reconstruction: A 21-Year Population-Based Study. Am. J. Sports Med. 2016, 44, 1502–1507. [Google Scholar] [CrossRef] [PubMed]
  17. Komnos, G.A.; Hantes, M.H.; Kalifis, G.; Gkekas, N.K.; Hante, A.; Menetrey, J. Anterior Cruciate Ligament Tear: Individualized Indications for Non-Operative Management. J. Clin. Med. 2024, 13, 6233. [Google Scholar] [CrossRef]
  18. Murray, M.M.; Fleming, B.C. Biology of Anterior Cruciate Ligament Injury and Repair: Kappa Delta Ann Doner Vaughn Award Paper 2013. J. Orthop. Res. 2013, 31, 1501–1506. [Google Scholar] [CrossRef]
  19. Georgiev, G.P.; Telang, M.; Landzhov, B.; Olewnik, Ł.; Slavchev, S.A.; LaPrade, R.F.; Ruzik, K.; Tubbs, R.S. The novel epiligament theory: Differences in healing failure between the medial collateral and anterior cruciate ligaments. J. Exp. Orthop. 2022, 9, 10. [Google Scholar] [CrossRef]
  20. Georgiev, G.P.; Kotov, G.; Iliev, A.; Kinov, P.; Angelova, J.; Landzhov, B. Comparison Between Operative and Non-Operative Treatment of the Medial Collateral Ligament: Histological and Ultrastructural Findings During Early Healing in the Epiligament Tissue in a Rat Knee Model. Cells Tissues Organs 2018, 206, 165–182. [Google Scholar] [CrossRef] [PubMed]
  21. Cao, M.; Stefanovic-Racic, M.; Georgescu, H.I.; Fu, F.H.; Evans, C.H. Does Nitric Oxide Help Explain the Differential Healing Capacity of the Anterior Cruciate, Posterior Cruciate, and Medial Collateral Ligaments? Am. J. Sports Med. 2000, 28, 176–182. [Google Scholar] [PubMed]
  22. Yoshida, M.; Fujii, K. Differences in Cellular Properties and Responses to Growth Factors Between Human ACL and MCL Cells. J. Orthop. Sci. 1999, 4, 293–298. [Google Scholar] [CrossRef]
  23. Shelbourne, K.D.; Gray, T. Anterior Cruciate Ligament Injury Combined with Medial Collateral Ligament, Posterior Cruciate Ligament, and/or Lateral Collateral Ligament Injury. In The Anterior Cruciate Ligament, 2nd ed.; Prodromos, C.C., Ed.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 393–398.e2. [Google Scholar]
  24. Zhang, J.; Pan, T.; Im, H.J.; Fu, F.H.; Wang, J.H. Differential properties of human ACL and MCL stem cells may be responsible for their differential healing capacity. BMC Med. 2011, 9, 68. [Google Scholar] [CrossRef] [PubMed]
  25. Georgiev, G.P.; Iliev, A.; Landzhov, B.; Dimitrova, I.N.; Kotov, G.; Malinova, L.; Ovtscharoff, W. Localization of Matrix Metalloproteinase-2 in Injured Medial Collateral Ligament Epiligament in Rat Knee. Compt. Rend. Acad. Bulg. Sci. 2017, 70, 273–278. [Google Scholar]
  26. Georgiev, G.P.; Kotov, G.; Iliev, A.; Slavchev, S.; Ovtscharoff, W.; Landzhov, B. A Comparative Study of the Epiligament of the Medial Collateral and the Anterior Cruciate Ligament in the Human Knee: Immunohistochemical Analysis of Collagen Type I and V and Procollagen Type III. Ann. Anat. 2019, 224, 88–96. [Google Scholar] [CrossRef]
  27. Georgiev, G.P.; Tubbs, R.S.; Olewnik, Ł.; Zielinska, N.; Telang, M.; Ananiev, J.; Dimitrova, I.N.; Slavchev, S.A.; Yordanov, Y.; LaPrade, R.F.; et al. A comparative study of the epiligament of the medial collateral and anterior cruciate ligaments in the human knee: Immunohistochemical analysis of CD 34, α-smooth muscle actin and vascular endothelial growth factor in relation to epiligament theory. Knee 2022, 39, 78–90. [Google Scholar] [CrossRef] [PubMed]
  28. Georgiev, G.P.; Yordanov, Y.; Olewnik, Ł.; Tubbs, R.S.; LaPrade, R.F.; Ananiev, J.; Slavchev, S.A.; Dimitrova, I.N.; Gaydarski, L.; Landzhov, B. Do the Differences in the Epiligament of the Proximal and Distal Parts of the Anterior Cruciate Ligament Explain Their Different Healing Capacities? Quantitative and Immunohistochemical Analysis of CD34 and α-SMA Expression in Relation to the Epiligament Theory. Biomedicines 2024, 12, 156. [Google Scholar] [CrossRef]
  29. Georgiev, G.P.; Yordanov, Y.; Gaydarski, L.; Tubbs, R.S.; Olewnik, Ł.; Zielinska, N.; Piagkou, M.; Ananiev, J.; Dimitrova, I.N.; Slavchev, S.A.; et al. Are There Any Differences in the Healing Capacity between the Medial Collateral Ligament’s (MCL) Proximal and Distal Parts in the Human Knee? Quantitative and Immunohistochemical Analysis of CD34, α-Smooth Muscle Actin (α-SMA), and Vascular Endothelial Growth Factor (VEGF) Expression Regarding the Epiligament (EL) Theory. Biomedicines 2024, 12, 659. [Google Scholar] [CrossRef]
  30. Iliev, A.; Kotov, G.; Stamenov, N.; Landzhov, B.; Kirkov, V.; Georgiev, G.P. A Comparative Immunohistochemical and Quantitative Study of the Epiligament of the Medial Collateral and Anterior Cruciate Ligament in Rat Knee. Int. J. Morphol. 2021, 39, 151–159. [Google Scholar] [CrossRef]
  31. Woo, S.L.; Vogrin, T.M.; Abramowitch, S.D. Healing and Repair of Ligament Injuries in the Knee. J. Am. Acad. Orthop. Surg. 2000, 8, 364–372. [Google Scholar] [CrossRef]
  32. Chamberlain, C.S.; Crowley, E.M.; Kobayashi, H.; Eliceiri, K.W.; Vanderby, R. Quantification of Collagen Organization and Extracellular Matrix Factors within the Healing Ligament. Microsc. Microanal. 2011, 17, 779–787. [Google Scholar] [CrossRef] [PubMed]
  33. Creighton, R.A.; Spang, J.T.; Dahners, L.E. Basic Science of Ligament Healing: Medial Collateral Ligament Healing with and without Treatment. Sports Med. Arthrosc. Rev. 2005, 13, 145–150. [Google Scholar] [CrossRef]
  34. Bray, R.C.; Fisher, A.W.; Frank, C.B. Fine Vascular Anatomy of Adult Rabbit Knee Ligaments. J. Anat. 1990, 172, 69–79. [Google Scholar] [PubMed]
  35. Chowdhury, P.; Matyas, J.R.; Frank, C.B. The “Epiligament” of the Rabbit Medial Collateral Ligament: A Quantitative Morphological Study. Connect. Tissue Res. 1991, 27, 33–50. [Google Scholar] [CrossRef]
  36. Lyon, R.M.; Akeson, W.H.; Amiel, D.; Kitabayashi, L.R.; Woo, S.L. Ultrastructural Differences Between the Cells of the Medial Collateral and the Anterior Cruciate Ligaments. Clin. Orthop. Relat. Res. 1991, 272, 279–286. [Google Scholar] [CrossRef]
  37. Amiel, D.; Nagineni, C.N.; Choi, S.H.; Lee, J. Intrinsic Properties of ACL and MCL Cells and Their Responses to Growth Factors. Med. Sci. Sports Exerc. 1995, 27, 844–851. [Google Scholar] [CrossRef]
  38. Bray, R.C.; Leonard, C.A.; Salo, P.T. Correlation of Healing Capacity with Vascular Response in the Anterior Cruciate and Medial Collateral Ligaments of the Rabbit. J. Orthop. Res. 2003, 21, 1118–1123. [Google Scholar] [CrossRef] [PubMed]
  39. Furumatsu, T.; Hachioji, M.; Saiga, K.; Takata, N.; Yokoyama, Y.; Ozaki, T. Anterior Cruciate Ligament-Derived Cells Have High Chondrogenic Potential. Biochem. Biophys. Res. Commun. 2010, 391, 1142–1147. [Google Scholar] [CrossRef] [PubMed]
  40. Nishikawa, Y.; Kokubun, T.; Kanemura, N.; Takahashi, T.; Matsumoto, M.; Maruyama, H.; Takayanagi, K. Effects of Controlled Abnormal Joint Movement on the Molecular Biological Response in Intra-Articular Tissues During the Acute Phase of Anterior Cruciate Ligament Injury in a Rat Model. BMC Musculoskelet. Disord. 2018, 19, 175. [Google Scholar] [CrossRef] [PubMed]
  41. Chen, C.H. Graft Healing in Anterior Cruciate Ligament Reconstruction. Sports Med. Arthrosc. Rehabil. Ther. Technol. 2009, 1, 21. [Google Scholar] [CrossRef] [PubMed]
  42. Andrish, J.; Holmes, R. Effects of Synovial Fluid on Fibroblasts in Tissue Culture. Clin. Orthop. Relat. Res. 1979, 138, 279–283. [Google Scholar]
  43. Vavken, P.; Murray, M.M. The Potential for Primary Repair of the ACL. Sports Med. Arthrosc. Rev. 2011, 19, 44–49. [Google Scholar] [CrossRef] [PubMed]
Table 1. Comparison of the current knowledge and the EL theory on ACL healing failure.
Table 1. Comparison of the current knowledge and the EL theory on ACL healing failure.
AspectCurrent KnowledgeEL Theory
Structural CharacteristicsFocus on ligament ultrastructure differences compared to MCL cellsEL is structurally distinct from the ligament and hypercellular compared to it
Cellular ActivityLimited cellular proliferative capacity in ACL cellsEL contains dynamic fibroblasts producing collagen types I, III, V, and MMPs
VascularizationLimited blood supply to the ACL after traumaEL has a significantly higher density of blood vessels than the ligament
Nitric Oxide LevelsHigher levels in the ACL potentially inhibit healingNot addressed explicitly in the EL theory
Stem Cell PropertiesSpecific properties of ACL stem cells affect the healing potentialEL contains fibroblasts, fibrocytes, adipocytes, and neurovascular bundles
Matrix MetalloproteinasesDifferential expression of MMP-2, MMP-9, and MMP-13EL fibroblasts dynamically produce MMP-2 and MMP-9
Injury GapCells and blood vessels fail to fill the injury gap adequatelyEL penetrates the ligament via the endoligament
Collagen Fiber PropertiesNot emphasizedEL consists of small-diameter collagen fibers oriented in various directions.
LocationACL’s intra-articular position contributes to limited healingEL is a dynamic structure interacting with the ligament
Table 2. Summary of the structural, functional, and immunohistochemical differences between the EL of ACL and MCL.
Table 2. Summary of the structural, functional, and immunohistochemical differences between the EL of ACL and MCL.
Feature/MarkerProximal ACLMidsubstance ACLDistal ACLProximal MCLMidsubstance MCLDistal MCL
Cell DensityHigher than mid-substance, lower than distalLowest cell densityHigher than mid-substance, similar to proximalLower than distalSimilar to distalHigher than proximal
Cell Types PresentFibroblasts, fibrocytes, fewer neurovascular bundlesFibroblasts, fewer cell typesFibroblasts, fibrocytes, neurovascular bundles, adipocytesFibroblasts, fibrocytes, adipocytes, abundant neurovascular bundlesSimilar to distalHigher fibroblast and neurovascular bundle density
CD34 (Progenitor Cell Marker)Elevated expression, less prominent than distalLess prominent expressionHigh expression, supporting progenitor cell activityWeak expressionSimilar to proximalLow expression
α-Smooth Muscle Actin (α-SMA)Higher expression suggests a more significant role in tissue remodelingLow expressionElevated expression, supporting tissue remodelingLow expressionSimilar to proximalHigher expression, aiding remodeling
Collagen ExpressionStronger expression of key collagens (I, III, V)Weaker expression of key collagens (I, III, V)Stronger expression of key collagens (I, III, V)Stronger collagen expression, especially types I, III, VSimilar to distalStronger collagen expression, especially types I, III, V
Collagen Fiber PropertiesComposed of small-diameter collagen fibers, varied orientationsSmaller diameter, less active remodelingIt is composed of small-diameter collagen fibers oriented in different directions.Similar to ACL but more active remodeling, enhanced with higher cell density and vascularizationSimilar to distalMore active remodeling, greater fiber activity in response to healing
Matrix Metalloproteinase (MMP) ActivityMMP-2 and MMP-9 expression, facilitating remodelingMMP-2 and MMP-9 expressions are less effective in healingMMP-2 and MMP-9 expression, aiding in remodelingSimilar to ACLSimilar to distalActive MMP-2 and MMP-9, aiding superior healing capacity
VascularizationLimited, less vascularizedLeast vascularizedModerate vascularization, but less than distalMore robust vascularization than proximalSimilar to distalMore robust vascularization than proximal, aiding healing
Vascular Endothelial Growth Factor (VEGF)Low VEGF expression, less angiogenesisLimited expressionHigher VEGF expression, aiding angiogenesis and vasculogenesisVEGF is present but with no significant regional differencesSimilar to proximalVEGF presents enhanced regional blood vessel activity
Functional Role in HealingActive in remodeling and angiogenesisLess effective in healing due to low vascularity and cell densityActive in both tissue remodeling and angiogenesisProminent in healing through collagen synthesis, fibroblast recruitment, and tissue remodelingIt has a more substantial healing role but is limited compared to distalThe most significant healing role supporting repair through angiogenesis, remodeling, and progenitor cell activation
Overall Healing PotentialModerate healing aided by collagen and α-SMALimited, poor healing potentialHigh, due to elevated collagen synthesis and cellular activityModerate, depends on remodeling activity and fibroblast recruitmentHigh, yet less superior compared to distalExcellent, especially for more severe injuries with more active cellular support
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Georgiev, G.P.; Gaydarski, L.; Landzhov, B. Should We Accept the Epiligament Theory About the Differences in the Healing Potential of the Medial Collateral and the Anterior Cruciate Ligament? Biomedicines 2025, 13, 522. https://doi.org/10.3390/biomedicines13020522

AMA Style

Georgiev GP, Gaydarski L, Landzhov B. Should We Accept the Epiligament Theory About the Differences in the Healing Potential of the Medial Collateral and the Anterior Cruciate Ligament? Biomedicines. 2025; 13(2):522. https://doi.org/10.3390/biomedicines13020522

Chicago/Turabian Style

Georgiev, Georgi P., Lyubomir Gaydarski, and Boycho Landzhov. 2025. "Should We Accept the Epiligament Theory About the Differences in the Healing Potential of the Medial Collateral and the Anterior Cruciate Ligament?" Biomedicines 13, no. 2: 522. https://doi.org/10.3390/biomedicines13020522

APA Style

Georgiev, G. P., Gaydarski, L., & Landzhov, B. (2025). Should We Accept the Epiligament Theory About the Differences in the Healing Potential of the Medial Collateral and the Anterior Cruciate Ligament? Biomedicines, 13(2), 522. https://doi.org/10.3390/biomedicines13020522

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop